Cancer Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Pancreatic Cancer
European Regulatory Agency Grants Orphan Status to Morphotek(R)'s Farletuzumab and MORAb-009
April 29th, 2008
Morphotek(R), Inc., a subsidiary of Eisai Corporation of North America, announced that the European Commission has granted orphan drug status to the monoclonal antibodies -- farletuzumab (also known as MORAb-003) for the treatment of ovarian cancer and MORAb-009 for the treatment of pancreatic cancer. Farletuzumab is currently being evaluated in a Phase II efficacy study in patients with platinum sensitive ovarian cancer. In Phase I studies, farletuzumab was well tolerated in patients with advanced, platinum-resistant or refractory ovarian cancer over the course of the treatment period and clinical observations therein suggested pharmacological activity on the disease....
Source: Cancer Weekly (2008-04-29)
|
